05/10/2026 In Phase 3 EPCORE DLBCL-2 study, epcoritamab + R-CHOP significantly improved PFS in newly diagnosed DLBCL In Phase 3 EPCORE DLBCL-2 study, epcoritamab + R-CHOP significantly improved PFS in newly diagnosed DLBCL (Ref) Genmab and AbbVie reported positive Phase 3 EPCORE DLBCL-2 results, evaluating fixed treatment duration epcoritamab (T-cell engaging bispecific antibody) in combination with standard of care rituximab, cyclophosphamide, doxorubicin hydrochloride, vinc